Henry: Cancer Management in Small Animal Practice

Chapter 5: Clinical Trial Design and Access to Clinical Research Studies

References

  1. Bergman PJ, McKnight J, Novosad A, et al: Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial, Clin Cancer Res 9:1284, 2003. Medline abstracts
  2. Porrello A, Cardelli P, Spugnini EP: Oncology of companion animals as a model for humans: An overview of tumor histotypes, J Exp Clin Cancer Res 25:97, 2006. Medline abstracts
  3. Bergman PJ, Camps-Palau MA, McKnight JA, et al: Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center, Vaccine 24:4582, 2006. Medline abstracts
  4. Khanna C, Hunter K: Modeling metastasis in vivo, Carcinogenesis 26:513, 2005. Medline abstracts
  5. Hansen K, Khanna C: Spontaneous and genetically engineered animal models; use in preclinical cancer drug development, Eur J Cancer 40:858, 2004. Medline abstracts
  6. American Society of Clinical Oncology policy statement: oversight of clinical research, J Clin Oncol 21:2377, 2003. Medline abstracts
  7. Girard P: Clinical trial simulation: a tool for understanding study failures and preventing them, Basic Clin Pharmacol Toxicol 96:228, 2005. Medline abstracts
  8. London CA, Hannah AL, Zadovoskaya R: Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies, Clin Cancer Res 9:2755, 2003. Medline abstracts
  9. Giacinit L, Lopez M, Giordano A: Clinical trials, Front Biosci 11:2918, 2006. Medline abstracts
  10. Lee JJ, Feng L: Randomized phase II designs in cancer clinical trials: current status and future directions, J Clin Oncol 23:4450, 2005. Medline abstracts
  11. Simon R, Maitournam A: Evaluating the efficiency of targeted designs for randomized clinical trials, Clin Cancer Res 10:6759, 2004. Medline abstracts
  12. Dobson JM, Blackwood LB, McInnes EF, et al: Prognostic variables in canine multicentric lymphosarcoma, J Small Anim Pract. 42:377, 2001. Medline abstracts
  13. Sargent DJ, Conley BA, Allegra C, Collette L: Clinical trial designs for predictive marker validation in cancer treatment trials, J Clin Oncol 23:2020, 2005. Medline abstracts
  14. Mandrekar SJ, Grothey A, Goetz MP, Sargent DJ: Clinical trial designs for prospective validation of biomarkers, Am J Pharmacogenomics 5:317, 2005. Medline abstracts
  15. Yuan Z, Chappell R: Isotonic designs for phase I cancer clinical trials with multiple risk groups, Clin Trials 1:499, 2004. Medline abstracts
  16. Green SJ, Pauler DK: Statistics in clinical trials, Curr Oncol Rep 6:36, 2004. Medline abstracts
  17. Thall PF: Recent advances in clinical trial design and analysis. Boston, 1995, Kluwer Academic Publishers.
  18. Ahn C: An evaluation of phase I cancer clinical trial designs, Stat Med 17:1537, 1998. Medline abstracts
  19. Eisenhauer EA, O’Dwyer PJ, Christian M, Humphrey JS: Phase I clinical trial design in cancer drug development, J Clin Oncol 18:684, 2000. Medline abstracts
  20. Vail DM: Veterinary Co-operative Oncology Group, Vet Compar Oncol 2:194, 2004. Medline abstracts
  21. Bell JG, Brady M, Copeland LJ: The ethics of reporting and disseminating results of clinical research trials, Cancer 100:1107, 2004. Medline abstracts
  22. Trotti A, Bentzen SM: The need for adverse effects reporting standards in oncology clinical trials, J Clin Oncol 22:19, 2004. Medline abstracts
  23. Fazzari M, Heller G, Scher HI: The phase II/III transition. Toward the proof of efficacy in cancer clinical trials, Control Clin Trials 21:360, 2000. Medline abstracts
  24. Ma BB, Britten CD, Siu LL: Clinical trial designs for targeted agents, Hematol Oncol Clin North Am 16:1287, 2002. Medline abstracts
  25. Sargent D, Allegra C: Issues in clinical trial design for tumor marker studies, Semin Oncol 29:222, 2002. Medline abstracts
  26. Seymour L: The design of clinical trials for new molecularly targeted compounds: progress and new initiatives, Curr Pharm Des 8:2279, 2002. Medline abstracts
  27. Simon RM, Steinberg SM, Hamilton M, et al: Clinical trial designs for the early clinical development of therapeutic cancer vaccines, J Clin Oncol 19:1848, 2001. Medline abstracts
  28. Simon C, Eder M, Raiz P, et al: Informed consent for pediatric leukemia research: clinician perspectives, Cancer 92:691, 2001. Medline abstracts
  29. Geyer SJ: Consent forms for oncology trials, N Engl J Med 348:1496; author reply 1496, 2003. Medline abstracts
  30. Brown RF, Butow PN, Ellis P, et al: Seeking informed consent to cancer clinical trials: describing current practice, Soc Sci Med 58:2445, 2004. Medline abstracts
  31. Cannistra SA: The ethics of early stopping rules: who is protecting whom? J Clin Oncol 22:1542, 2004. Medline abstracts
  32. Cuzick J, Howell A, Forbes J: Early stopping of clinical trials, Breast Cancer Res 7: 181, 2005. Medline abstracts
  33. Kadane JB: Bayesian methods and ethics in a clinical trial design. New York, 1996, J. Wiley & Sons.
  34. Bekele BN, Shen YA: Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial, Biometrics 61:343, 2005. Medline abstracts